NewAmsterdam Pharma Company N.V. (NAMS)
Nasdaq: NAMS · Pharmaceutical Preparations · Narrden, NL · filing with the SEC since 2022
Who owns NewAmsterdam Pharma Company N.V.
As filed with the SECHolders of 5% or more
5
Capital World Investors holds 10.4% of Common Stock, as its SCHEDULE 13G/A filed Jun 4, 2026 says.
Directors and officers
13
report now, of 19 people on the record since 2023. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Capital World Investors
SCHEDULE 13G/A · filed Jun 4, 2026 · Common Stock · 8.7% in Nov 13, 2025
RA Capital Management, L.P.
SCHEDULE 13G/A · filed May 15, 2025 · Ordinary Shares, nominal value EUR0.12 per share · 9.9% in Feb 14, 2025
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 7.6% in May 6, 2026
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13D/A · filed Sep 22, 2026 · Ordinary Shares, nominal value EUR0.12 per share · 7.7% in Nov 4, 2025
ForGrowth NAP B.V.
SCHEDULE 13D/A · filed Sep 30, 2025 · Ordinary Shares, Nominal value 0.12 per share · 9.4% in Aug 12, 2025
Viking Global Investors LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Ordinary Shares, nominal value EUR0.12 per share · reported falling below 5%, from 6.5% in Feb 14, 2025
BCLS Fund III Investments, LP
SCHEDULE 13D/A · filed May 14, 2026 · Ordinary Shares, nominal value Euro 0.12 per share · reported falling below 5%, from 4.7% in Dec 4, 2025
What NAMS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
NewAmsterdam Pharma Holding B.V. and NewAmsterdam Pharma Investment Corporation
A company bought · acquisition · owns, named in the 10-K filed Feb 18, 2026
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Feb 18, 2026.
Insider tradesForm 4
43sales
1purchases
36sales on a scheduled plan
6people selling
$63.3Msold, in dollars
$200,000bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Davidson Michael H. | Chief Executive Officer | 9 | $25.3M | 8 | 1 | $200,000 |
| Kooij Louise Frederika | Chief Accounting Officer | 16 | $16.8M | 16 | 0 | $0 |
| Kastelein Johannes Jacob Pieter | Chief Scientific Officer | 8 | $15.5M | 6 | 0 | $0 |
| Somaiya Mayur Ian | Chief Financial Officer | 6 | $3.4M | 6 | 0 | $0 |
| Lange Louis G | director | 3 | $2.2M | 0 | 0 | $0 |
| Smither John W | director | 1 | $0 | 0 | 0 | $0 |